A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news.
The first blood test designed to assist physicians in determining whether a patient has Alzheimer’s disease is now available in most US states, the company C2N Diagnostics announced October 29. The test measures biomarkers that frequently reflect the presence of amyloid plaques in the brain—a hallmark of Alzheimer’s—as well as the presence of a gene variant that increases the risk of the disease.
An artificial intelligence (AI) tool was able to accurately predict Alzheimer’s disease almost eight years before a person was diagnosed, according to a study recently published in the journal EClinicalMedicine, and researchers say the tool could help providers to identify patients in early stages of the disease.
A team led by Dr Laura Ferraiuolo of The University of Sheffield have found that AI could be used to assess and monitor potential patients. Specifically, machines could be programmed to recognise Alzheimer’s by looking at an image of a patient’s brain, as well as assessing their movements and speech to determine if they are likely to be suffering from the condition before symptoms progress.
Clinical trials of Alzheimer’s medicines have failed frequently but now researchers believe that this may have been caused by the drugs given too late. So if they could just develop a test that would detect Alzheimer’s earlier, it would make the drugs that have failed for use later in the process, so much more productive.
A new blood test detected Alzheimer’s disease as accurately as expensive brain scans or spinal taps, raising the possibility for a new, inexpensive option to diagnose the most common form of dementia, researchers said.
An experimental blood test was highly accurate at distinguishing people with Alzheimer’s disease from those without it in several studies, boosting hopes that there soon may be a simple way to help diagnose this most common form of dementia
There may not be a cure yet for Alzheimer’s disease but now there is a faster way to get an early diagnosis.
Neurosciences Medical Clinic now provides a NEW service that allows for the early detection of Alzheimer’s Disease. Science allows us to combine a series of physical, memory, imaging and genetic testing in order to determine if someone has Alzheimer’s Disease in order to prepare for what is to come later on in life.
Please Contact Neurosciences Medical Clinic at 786-600-7004 in order to learn more or follow their social media pages @NeurosciencesMedicalClinic or click on their webpage: Neurosciencesclinics.com. The clinic provides free initial screening.
Within a few years, doctors will be able to remotely evaluate patients for their risk of developing Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia — without having to hook them up to expensive, cumbersome machines generally found only in hospitals. That’s the vision of Israeli entrepreneur Nathan Intrator, CEO of Neurosteer. “Millions of people suffer from neurodegenerative diseases, and as life expectancy goes up, that number will only increase,”
When it comes to Alzheimer’s, what happens first: beta amyloid plaques, or the visible personality and cognitive changes common with the disease? Researchers have long believed that amyloid drives neurodegeneration in the brain. But it’s possible that subtle changes in a person’s thinking abilities may actually precede the development of beta-amyloid protein, providing more clues to the complexity of the disease, according to a new study.
If you’ve noticed changes in yourself and are concerned about your health—particularly if it’s related to memory, thinking or behavior—it can be difficult to know what to do Read the story in our link for today for some guidance
Researchers at the National University of Singapore (NUS) are working on a blood test called the APEX system, which took two years to develop, to detect an early-stage molecular marker of the brain-robbing disease — the aggregated amyloid beta
Results from a study of nearly 60,000 individuals suggest those at higher risk of developing Alzheimer’s disease due to family history may demonstrate changes in memory performance as early as their 20s.
A study found that consistently worrying about our memory—think rushing to WebMD every day to determine whether or not occasionally forgetting the route to a friend’s house means we’re destined to develop Alzheimer’s—is a sign that we may have a lower risk of receiving an Alzheimer’s diagnosis. The study found that forgetting your own forgetfulness is more concerning and could be an early sign of dementia.
A survey released this week by the Alzheimer’s Association finds that nearly 90 percent of Americans say they would want others to tell them if they were showing signs of memory loss or other symptoms of dementia. And yet, nearly three quarters of Americans say having that conversation would be “challenging” for them.
In the U.S., older people with dementia are usually told they have Alzheimer’s disease.
But a range of other brain diseases can also impair thinking and memory and judgment, according to scientists attending a summit on dementias held Thursday and Friday at the National Institutes of Health.
A team of researchers from Australia, the U.K. and Sweden has found a possible method to test blood samples for Alzheimer’s disease before symptoms appear. In their paper published in the journal Science Advances, the group describes their testing system and its performance.
Dr. Salloway was part of a group that came out with new guidelines advising physicians to prescribe spinal taps for people who either have memory loss or have a family history, as a way to diagnose Alzheimer’s — getting them into prevention trials sooner rather than later.